Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Co.'s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). We show 25 historical shares outstanding datapoints in our FULC shares outstanding history coverage, used to compute FULC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing FULC market cap history over the course of time is important for investors
interested in comparing FULC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of FULC versus a peer is one thing; comparing
FULC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like FULC can fluctuate over the course of history.
With this page we aim to empower investors researching FULC by allowing them to research the FULC market cap history. |
Free FULC Email Alerts:
Video: The Importance of Market Cap
